NeuClone is currently developing a deep pipeline of biosimilars across a variety of therapeutic indications. Ten of our biosimilar products are being co-developed in collaboration with Serum Institute of India. NeuClone is also developing an additional range of biosimilars independently.
The development stage of eight products with Serum Institute are outlined below.
Herceptin®
Trastuzumab
Stelara®
Ustekinumab
Prolia®/XGEVA®
Denosumab
Synagis®
Palivizumab
Perjeta®
Pertuzumab
Opdivo®
Nivolumab
Keytruda®
Pembrolizumab
Humira®
Adalimumab
12 other products in development.
Early Preclinical
Late Preclinical
Process Scale-up
Phase 1 – 2018
Early Preclinical
Late Preclinical
Process Scale-up
Phase 1 – 2019
Early Preclinical
Late Preclinical
Process Scale-up
Early Preclinical
Late Preclinical
Process Scale-up
Early Preclinical
Late Preclinical
Process Scale-up
Early Preclinical
Late Preclinical
Process Scale-up
Early Preclinical
Late Preclinical
Process Scale-up
Early Preclinical
Late Preclinical